Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPISTRY phase II tumor-agnostic precision oncology platform trial
NL-OMON51441Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Jan 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of entrectinib, alectinib, atezolizumab, trastuzumab emtansine, idasanutlin and 3 more in Nonhematologic neoplasms (10 cohorts), sponsored by Roche. Primary endpoint: Efficacy in biomarker-positive advanced or metastatic solid tumors. Planned start Jan 2022; status: withdrawn.
02
Drugs
entrectinibalectinibatezolizumabtrastuzumab emtansineidasanutlin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON51441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51441.